Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Rischin on the FDA Approval of Cemiplimab for CSCC

September 29th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.

FDA Approves Cemiplimab for CSCC

September 29th 2018

The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Adjuvant Therapy for Melanoma: Who, What, When?

September 28th 2018

More patients than ever before may now be good candidates for adjuvant therapy and derive long-term benefits from it, but new data and expanding treatment options have led to many new questions on how to optimize treatment for melanoma.

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

September 27th 2018

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

Dr. Eggermont Discusses Impact of Pembrolizumab in Melanoma

September 24th 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab in melanoma.

Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma

September 22nd 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Binimetinib/Encorafenib Combo Approved in Europe for BRAF+ Melanoma

September 21st 2018

The European Commission has approved the combination of encorafenib (Braftovi) and binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.

FDA Grants Pembrolizumab Priority Review for Merkel Cell Carcinoma

September 4th 2018

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for the treatment of pediatric and adult patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

September 4th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma

August 31st 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.

Encorafenib/Binimetinib Combo Shows Best-In-Class Efficacy in Melanoma

August 31st 2018

Keith T. Flaherty, MD, discusses the clinical implications of the COLUMBUS trial of encorafenib plus binimetinib in patients with BRAF-mutated melanoma.

Cemiplimab Offers Hope in Metastatic CSCC

August 31st 2018

Danny Rischin, MD, MBBS, FRACP, discusses the potential for cemiplimab as a novel PD-1 inhibitor for patients with metastatic and locally advanced cutaneous squamous cell carcinoma.

Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma

August 31st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Adjuvant Dabrafenib/Trametinib Approved in Europe for BRAF+ Melanoma

August 29th 2018

The European Commission has approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with BRAF V600–positive stage III melanoma.

Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

August 21st 2018

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

Dr. Stilwill on Findings from the 2018 ASCO Annual Meeting in Melanoma

August 1st 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses exciting findings in melanoma from the 2018 ASCO Annual Meeting.

Adjuvant Nivolumab Approved in Europe for Melanoma

July 31st 2018

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.

Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma

July 31st 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.

Adjuvant Dabrafenib/Trametinib Nears European Approval for BRAF+ Melanoma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of dabrafenib and trametinib for the adjuvant treatment of adult patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.